Brought to you by 
AstraZeneca, UPenn partner for tau-mediated Alzheimer's; deal later ends
15 Jan 2013
Executive Summary
AstraZeneca PLC and the University of Pennsylvania School of Medicine have agreed to work together on the development of new therapeutics for Alzheimer's disease. The collaboration comes after a successful three-year alliance signed in 2006 under which the entities researched various CNS conditions including addiction, cognition, anxiety, depression, and stress-related disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca, UPenn partner for tau-mediated Alzheimer's; deal later ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice